Literature DB >> 11250867

SB-334867-A: the first selective orexin-1 receptor antagonist.

D Smart1, C Sabido-David, S J Brough, F Jewitt, A Johns, R A Porter, J C Jerman.   

Abstract

The pharmacology of various peptide and non-peptide ligands was studied in Chinese hamster ovary (CHO) cells stably expressing human orexin-1 (OX(1)) or orexin-2 (OX(2)) receptors by measuring intracellular calcium ([Ca(2+)](i)) using Fluo-3AM. Orexin-A and orexin-B increased [Ca(2+)](i) in CHO-OX(1) (pEC(50)=8.38+/-0.04 and 7.26+/-0.05 respectively, n=12) and CHO-OX(2) (pEC(50)=8.20+/-0.03 and 8.26+/-0.04 respectively, n=8) cells. However, neuropeptide Y and secretin (10 pM - 10 microM) displayed neither agonist nor antagonist properties in either cell-line. SB-334867-A (1-(2-Methyylbenzoxanzol-6-yl)-3-[1,5]naphthyridin-4-yl-urea hydrochloride) inhibited the orexin-A (10 nM) and orexin-B (100 nM)-induced calcium responses (pK(B)=7.27+/-0.04 and 7.23+/-0.03 respectively, n=8), but had no effect on the UTP (3 microM)-induced calcium response in CHO-OX(1) cells. SB-334867-A (10 microM) also inhibited OX(2) mediated calcium responses (32.7+/-1.9% versus orexin-A). SB-334867-A was devoid of agonist properties in either cell-line. In conclusion, SB-334867-A is a non-peptide OX(1) selective receptor antagonist.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11250867      PMCID: PMC1572677          DOI: 10.1038/sj.bjp.0703953

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  10 in total

1.  Orexins: a new family of neuropeptides.

Authors:  D Smart
Journal:  Br J Anaesth       Date:  1999-11       Impact factor: 9.166

2.  Neurons containing hypocretin (orexin) project to multiple neuronal systems.

Authors:  C Peyron; D K Tighe; A N van den Pol; L de Lecea; H C Heller; J G Sutcliffe; T S Kilduff
Journal:  J Neurosci       Date:  1998-12-01       Impact factor: 6.167

3.  The hypocretins are weak agonists at recombinant human orexin-1 and orexin-2 receptors.

Authors:  D Smart; J C Jerman; S J Brough; W A Neville; F Jewitt; R A Porter
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

4.  Characterization of recombinant human orexin receptor pharmacology in a Chinese hamster ovary cell-line using FLIPR.

Authors:  D Smart; J C Jerman; S J Brough; S L Rushton; P R Murdock; F Jewitt; N A Elshourbagy; C E Ellis; D N Middlemiss; F Brown
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

5.  Hypothalamic hypocretin (orexin): robust innervation of the spinal cord.

Authors:  A N van den Pol
Journal:  J Neurosci       Date:  1999-04-15       Impact factor: 6.167

6.  Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.

Authors:  T Sakurai; A Amemiya; M Ishii; I Matsuzaki; R M Chemelli; H Tanaka; S C Williams; J A Richardson; G P Kozlowski; S Wilson; J R Arch; R E Buckingham; A C Haynes; S A Carr; R S Annan; D E McNulty; W S Liu; J A Terrett; N A Elshourbagy; D J Bergsma; M Yanagisawa
Journal:  Cell       Date:  1998-02-20       Impact factor: 41.582

7.  Orexins suppress catecholamine synthesis and secretion in cultured PC12 cells.

Authors:  T Nanmoku; K Isobe; T Sakurai; A Yamanaka; K Takekoshi; Y Kawakami; K Ishii; K Goto; T Nakai
Journal:  Biochem Biophys Res Commun       Date:  2000-08-02       Impact factor: 3.575

8.  Sensitivity of orexin-A binding to phospholipase C inhibitors, neuropeptide Y, and secretin.

Authors:  J K Kane; H Tanaka; S L Parker; M Yanagisawa; M D Li
Journal:  Biochem Biophys Res Commun       Date:  2000-06-16       Impact factor: 3.575

9.  The novel brain neuropeptide, orexin-A, modulates the sleep-wake cycle of rats.

Authors:  D C Piper; N Upton; M I Smith; A J Hunter
Journal:  Eur J Neurosci       Date:  2000-02       Impact factor: 3.386

10.  Presynaptic and postsynaptic actions and modulation of neuroendocrine neurons by a new hypothalamic peptide, hypocretin/orexin.

Authors:  A N van den Pol; X B Gao; K Obrietan; T S Kilduff; A B Belousov
Journal:  J Neurosci       Date:  1998-10-01       Impact factor: 6.167

  10 in total
  97 in total

Review 1.  Chemistry and biology of orexin signaling.

Authors:  Thomas Kodadek; Di Cai
Journal:  Mol Biosyst       Date:  2010-06-07

2.  Ligand-induced internalization of the orexin OX(1) and cannabinoid CB(1) receptors assessed via N-terminal SNAP and CLIP-tagging.

Authors:  Richard J Ward; John D Pediani; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

3.  Antagonism of orexin 1 receptors eliminates motor hyperactivity and improves homing response acquisition in juvenile rats exposed to alcohol during early postnatal period.

Authors:  Georg M Stettner; Leszek Kubin; Denys V Volgin
Journal:  Behav Brain Res       Date:  2011-03-21       Impact factor: 3.332

Review 4.  Orexin receptors: pharmacology and therapeutic opportunities.

Authors:  Thomas E Scammell; Christopher J Winrow
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011       Impact factor: 13.820

5.  Discrete cue-conditioned alcohol-seeking after protracted abstinence: pattern of neural activation and involvement of orexin₁ receptors.

Authors:  B Jupp; E Krstew; G Dezsi; A J Lawrence
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

6.  Arachidonic acid release mediated by OX1 orexin receptors.

Authors:  Pauli M Turunen; Marie E Ekholm; Pentti Somerharju; Jyrki P Kukkonen
Journal:  Br J Pharmacol       Date:  2009-12-04       Impact factor: 8.739

7.  Orexins stimulate steroidogenic acute regulatory protein expression through multiple signaling pathways in human adrenal H295R cells.

Authors:  Manjunath Ramanjaneya; Alex C Conner; Jing Chen; Peter R Stanfield; Harpal S Randeva
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

Review 8.  Intranasal administration of orexin peptides: Mechanisms and therapeutic potential for age-related cognitive dysfunction.

Authors:  Coleman B Calva; Jim R Fadel
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

Review 9.  Therapeutics development for addiction: Orexin-1 receptor antagonists.

Authors:  David A Perrey; Yanan Zhang
Journal:  Brain Res       Date:  2018-08-24       Impact factor: 3.252

10.  Analgesic effect of intrathecally administered orexin-A in the rat formalin test and in the rat hot plate test.

Authors:  Tatsuo Yamamoto; Natsuko Nozaki-Taguchi; Tanemichi Chiba
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.